Insider Buying: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Major Shareholder Purchases 1,666,666 Shares of Stock

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) major shareholder Brightstar Associates Llc bought 1,666,666 shares of the firm’s stock in a transaction that occurred on Tuesday, January 24th. The shares were acquired at an average price of $18.00 per share, with a total value of $29,999,988.00. Following the purchase, the insider now owns 19,718,014 shares in the company, valued at $354,924,252. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Deciphera Pharmaceuticals Trading Up 1.1 %

Deciphera Pharmaceuticals stock traded up $0.20 during mid-day trading on Tuesday, hitting $18.05. The stock had a trading volume of 954,943 shares, compared to its average volume of 1,281,729. The stock has a market capitalization of $1.22 billion, a PE ratio of -5.22 and a beta of 0.73. Deciphera Pharmaceuticals, Inc. has a 12 month low of $6.51 and a 12 month high of $22.76. The stock has a 50-day simple moving average of $17.03 and a two-hundred day simple moving average of $16.53.

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.02. Deciphera Pharmaceuticals had a negative net margin of 177.53% and a negative return on equity of 63.88%. The company had revenue of $35.97 million during the quarter, compared to analysts’ expectations of $33.29 million. Sell-side analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

DCPH has been the subject of a number of research reports. SVB Leerink raised their price objective on Deciphera Pharmaceuticals from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 4th. Stifel Nicolaus raised their target price on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the stock a “hold” rating in a research report on Tuesday, September 27th. Jonestrading upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 6th. Barclays boosted their target price on shares of Deciphera Pharmaceuticals from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Wednesday, January 4th. Finally, Guggenheim upgraded shares of Deciphera Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 target price for the company in a research report on Wednesday, January 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Deciphera Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $21.44.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

Several institutional investors have recently modified their holdings of DCPH. Goldman Sachs Group Inc. grew its position in shares of Deciphera Pharmaceuticals by 356.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 3,663,819 shares of the company’s stock worth $48,179,000 after buying an additional 2,861,642 shares during the period. Federated Hermes Inc. grew its position in shares of Deciphera Pharmaceuticals by 125.5% during the 1st quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company’s stock worth $18,161,000 after buying an additional 1,090,368 shares during the period. BlackRock Inc. raised its holdings in Deciphera Pharmaceuticals by 27.6% during the 1st quarter. BlackRock Inc. now owns 4,845,376 shares of the company’s stock worth $44,917,000 after buying an additional 1,047,807 shares during the period. Assenagon Asset Management S.A. raised its holdings in Deciphera Pharmaceuticals by 99.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,403,821 shares of the company’s stock worth $25,971,000 after buying an additional 699,071 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its holdings in Deciphera Pharmaceuticals by 12.0% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 6,250,964 shares of the company’s stock worth $82,200,000 after buying an additional 670,508 shares during the period. 72.66% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.